News Commentary | December 13, 2019
The funding comes just a few weeks after the company announced it is expanding into dairy fats. While this event is a win for cellular agriculture, it underscores the capital‑intensive nature of scaling the production approach. As a reference, the most highly funded plant‑based dairy company, Ripple... Not part of subscription
News Commentary | December 20, 2019
This investment round was co‑led by M Ventures, the corporate venture arm of Merck, along with Agronomics. This is M Ventures' second investment in the cellular agriculture space, having previously invested in Mosa Meat, a cultured meat startup. Legendairy is using synthetic biology and fermentation... Not part of subscription
News Commentary | August 17, 2020
New investor Coatue led the round, which comes only four months after Impossible raised a $500 million Series F round. Major company updates include over 60× retail footprint expansion in the U.S., increased presence of Impossible Sausage up to 22,000 restaurants, and new items in its R&D ... To read more, click here.
by Harini Venkataraman
This Series A round was led by Novo Holdings, joined by Roquette Ventures and Unovis Asset Management, and will help the Dutch startup to focus on R&D as well as scale up production of its mycoprotein ingredient "Fermotein." It hopes to commercialize Fermotein upon regulatory approval by 2021 in the U.S. and 2022 in Europe. This investment comes on the heels of Meati Foods' $28 million Series A, indicating the growing momentum for mycoproteins. Mycoproteins are emerging as a contender in the plant-based meat space as they look to fill the existing gaps in terms of texture and nutrition profile, but factors like allergenicity, regulatory approval, and consumer sentiment will play a crucial role in their commercial success.
For the original news article, click here .